Charles J. Lenz

TL;DR: Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (VTE) and apixaban is approved for the treatment of acute VTE.

TL;DR: The main aim of the ADAM-VTE trial is to test the hypothesis that apixaban is associated with a significantly lower rate of major bleeding compared to dalteparin in the treatment of cancer patients with acute VTE.

TL;DR: The VTE recurrence and bleeding rates for rivaroxaban and apixaban used in Vte‐AL are not different from those in patients with VTE‐TL and similar to that for enoxaparin.

TL;DR: The striking association with cancer adversely affects overall survival rates in patients with ovarian vein thrombosis, and venous thromboembolism recurrence rates argue for anticoagulation with a direct oral antICOagulant or vitamin K antagonist, particularly in those with a history of venousThrombolism.

TL;DR: Oral apixaban therapy was associated with very low rates of bleeding and significantly lower VTE recurrence with superior quality of life outcome measures compared to parenteral dalteparin in the treatment of cancer associated VTE.